Suppression of Epigenetic Brain Proteins Induces Autism-Like Syndrome
Regulation of a family of brain proteins known as bromodomain and extra-terminal domain containing transcription regulators (BETs) plays a key role in normal cognition and behavior, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published advanced online on September 21 and in print October 19 in The Journal of Experimental Medicine.
The Mount Sinai study focuses on epigenetics, the study of changes in the action of human genes caused by molecules that regulate when, where and to what degree our genetic material is activated, rather than focusing on genetic changes in the DNA code we inherit from our parents.
While scientists have traditionally focused on finding individual genes responsible for Autism Spectrum Disorders (ASD), recent research has found links between epigenetic regulation and ASD in human patients. Such regulation derives, in part, from the function of specialized protein complexes that bind to specific DNA sequences and either encourage or shut down the expression of a given gene.
Mount Sinai researchers found that BETs, a family of epigenetic regulators that bind to many different genes and contribute to the copying of these genes into messenger RNA, the template used by the cell to make proteins, play a key role in the regulation of normal neuronal development and function. The Mount Sinai study was conducted using a new type of pharmacological compound that does not inactivate BET proteins but, rather, prevents them from binding to the genes.
The research team developed a novel, highly specific, brain-permeable inhibitor of BET proteins called I-BET858. The compound was initially tested on in vitro cultured mouse neurons. The researchers found that it affected the function of a particular group of genes with known links to neuron development and synaptic functions. Importantly a significant number of the affected genes have been linked to ASD in humans. Subsequently, the study team evaluated the effect of I-BET858 when injected into mice. They found the compound was able to trigger selective changes in neuronal gene expression in the brain followed by development of an ASD-like syndrome.
“We found that chronic daily administration of I-BET858 in young mice led to the development of behavioral abnormalities consistent with an autism-like syndrome, including reduced sociability and preference for social novelty ” says Anne Schaefer, MD, PhD, Assistant Professor in the Department of Neuroscience and Psychiatry at the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai, who led the study.
“One of the most important outcomes of our study is that we found a link between I-BET858-induced ASD and the altered function of a rather limited group of genes,” says Dr. Schaefer. “Furthermore, our findings reinforce the idea that ASD could be caused not only by genetic alteration, but by environmental factors that reduce the efficiency of gene transcription into full length RNA during brain development. “
These studies also suggest that pharmacological modeling of ASD in mice provides a valuable tool for the identification of genes that may play a pivotal role in the disease pathology or for the development of novel drugs targeting ASD.
Researchers from the GlaxoSmithKline and The Rockefeller University collaborated on this study.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation.
The System includes approximately 7,100 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of 3 medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 13 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked in six out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke's and Mount Sinai West are ranked regionally.